Results from a 2-year centralized tolcapone liver enzyme monitoring program

Clinical Neuropharmacology

Volumn 30, Issue 5, 2007, Pages 281-286

  Lew, Mark F ^a   Kricorian, Greg ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Valeant Pharmaceuticals International   (United States)

Author keywords

Catechol O methyltransferase inhibitor; Hepatotoxicity; Liver enzyme tests; Parkinson disease; Tolcapone

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME; TOLCAPONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; DATA BASE; DRUG MONITORING; FEMALE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL METHOD; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

ALANINE TRANSAMINASE; ANTIPARKINSON AGENTS; ASPARTATE AMINOTRANSFERASES; BENZOPHENONES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; NITROPHENOLS; PARKINSONIAN DISORDERS; RETROSPECTIVE STUDIES;

EID: 34848902047     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e318149f290     Document Type: Article

References (16)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
2. Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994;25:813-824.
3. Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf 2003;26:743-747.
4. Dingemanse J, Jorga K, Zurcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-262.
5. Dingemanse J, Jorga K, Zurcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55.
6. Kurth MC, Adler CH, Hilaire MS, et al. For the Tolcapone Fluctuator Study Group I. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-87.
7. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
8. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-1071.
9. Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs 2005;19:165-184.
10. Waters CH, Kurth M, Bailey P, et al. For the Tolcapone Stable Study Group. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49:665-671.
11. Dupont E, Burgunder JM, Findley LJ, et al. For the Tolcapone in Parkinson's Disease Study Group II (TIPS II). Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 1997;12:928-934.
12. Olanow CW and the Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch Neurol 2000;57:263-267.
13. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958.
14. FDA talk paper: new warnings for Parkinson's drug, Tasmar [T98-81]. November 16, 1998. Available at: http://www.fda.gov/bbs/topics/answers/ans00924. html. Accessed August 15, 2006.
15. Watts R, Kricorian G. Evaluation of liver-related adverse events with tolcapone: a review of 7-years of worldwide safety data. Paper presented at: 2005 World Congress of Neurology; November 9, 2005; Sydney, Australia.
16. Tasmar (tolcapone) tablets [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals International; 2006.